April 5, 2016
RegMed’s close: the sector finds value by selling …
April 5, 2016
Bellicum Pharma (BLCM) Data shows BPX-501 Cells help adaptive immunity - BUY
April 5, 2016
Lower open expected; will RegMed – splish, splash, are we about to take a bath?
March 31, 2016
RegMed’s close: Q1/16 ends with oversold momentum driving the sector higher
March 31, 2016
Lower open expected; RegMed sector’s crucible, end of the Q, creditable and actionable intel enclosed
March 30, 2016
RegMed’s close: another day of price swings, by 3 pm we were down again
March 29, 2016
RegMed’s close: good news, the parachute deployed
March 24, 2016
Aduro Biotech (ADRO) and Incyte Corporation’s (INCY) first patient has been dosed in SEASCAPE’s P1/2 clinical study
March 23, 2016
RegMed’s close: the sector downdrafts, I can’t resist - a told you so!
March 21, 2016
RegMed’s close: low to average volatility pushes upside momentum
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.